Cell line · CVCL_0426
Papers81
1 to 20 of 81
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Surface modification of 3D‐printed polycaprolactone scaffolds with silk fibroin for bone tissue engineering | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal CircRNA_102619-miR-330-3p Interaction Regulates Osteosarcoma Progression and Metastasis by Forming the Lung Pre-Metastatic Niche. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An inertial-based spiral device for separating rare tumor cells from liquid biopsies. | Bioeng Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inference of lineage hierarchies, growth, and drug response mechanisms in cancer cell populations without tracking. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro. | J Bone Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. | Front Med (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. | Sci Prog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ldha Regulates Osteosarcoma Lung Metastasis through Hedgehog Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular mechanism of miR-27a-3p targeting FBXW7 regulating the malignant behavior of osteosarcoma cells. | Transl Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. | Cancer Rep (Hoboken) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| LAT1-Targeted Alpha Therapy Using 211At-AAMT for Bone and Soft Tissue Sarcomas. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. | Prostate | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0426/papers